MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project

for the M-SKIP Study Group

doi:10.1111/jdv.16869

MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project

for the M-SKIP Study Group

Epidemiology & Community Health

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	e135-e138
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	2
DOIs	https://doi.org/10.1111/jdv.16869
State	Published - Feb 2021

Bibliographical note

Funding Information:
This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF‐2016‐02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co‐financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC‐CT‐2006‐018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundació La Marató TV3' 201331‐30, Catalonia, Spain; a grant from 'Fundación Científica de la Asociación Española Contra el Cáncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.

Funding Information:
This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF-2016-02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundaci? La Marat? TV3' 201331-30, Catalonia, Spain; a grant from 'Fundaci?n Cient?fica de la Asociaci?n Espa?ola Contra el C?ncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1111/jdv.16869

Find It

Find It at U of M Libraries

Cite this

@article{02e73346174a498e875f10c902c50d2d,

title = "MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project",

author = "\{for the M-SKIP Study Group\} and I. Stefanaki and Stratigos, \{A. J.\} and Kypreou, \{K. P.\} and E. Evangelou and S. Gandini and P. Maisonneuve and D. Polsky and D. Lazovich and J. Newton-Bishop and Kanetsky, \{P. A.\} and S. Puig and Gruis, \{N. A.\} and P. Ghiorzo and C. Pellegrini and \{De Nicolo\}, A. and G. Ribas and G. Guida and Garcia-Borron, \{J. C.\} and Fargnoli, \{M. C.\} and H. Nan and Landi, \{M. T.\} and J. Little and F. Sera and S. Raimondi",

note = "Funding Information: This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF‐2016‐02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co‐financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017\_SGR\_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC‐CT‐2006‐018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundaci{\'o} La Marat{\'o} TV3' 201331‐30, Catalonia, Spain; a grant from 'Fundaci{\'o}n Cient{\'i}fica de la Asociaci{\'o}n Espa{\~n}ola Contra el C{\'a}ncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115. Funding Information: This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF-2016-02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017\_SGR\_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundaci? La Marat? TV3' 201331-30, Catalonia, Spain; a grant from 'Fundaci?n Cient?fica de la Asociaci?n Espa?ola Contra el C?ncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.",

year = "2021",

month = feb,

doi = "10.1111/jdv.16869",

language = "English (US)",

volume = "35",

pages = "e135--e138",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - MC1R variants in relation to naevi in melanoma cases and controls

T2 - a pooled analysis from the M-SKIP project

AU - for the M-SKIP Study Group

AU - Stefanaki, I.

AU - Stratigos, A. J.

AU - Kypreou, K. P.

AU - Evangelou, E.

AU - Gandini, S.

AU - Maisonneuve, P.

AU - Polsky, D.

AU - Lazovich, D.

AU - Newton-Bishop, J.

AU - Kanetsky, P. A.

AU - Puig, S.

AU - Gruis, N. A.

AU - Ghiorzo, P.

AU - Pellegrini, C.

AU - De Nicolo, A.

AU - Ribas, G.

AU - Guida, G.

AU - Garcia-Borron, J. C.

AU - Fargnoli, M. C.

AU - Nan, H.

AU - Landi, M. T.

AU - Little, J.

AU - Sera, F.

AU - Raimondi, S.

N1 - Funding Information: This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF‐2016‐02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co‐financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC‐CT‐2006‐018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundació La Marató TV3' 201331‐30, Catalonia, Spain; a grant from 'Fundación Científica de la Asociación Española Contra el Cáncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115. Funding Information: This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF-2016-02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundaci? La Marat? TV3' 201331-30, Catalonia, Spain; a grant from 'Fundaci?n Cient?fica de la Asociaci?n Espa?ola Contra el C?ncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85090227330

UR - https://www.scopus.com/pages/publications/85090227330#tab=citedBy

U2 - 10.1111/jdv.16869

DO - 10.1111/jdv.16869

M3 - Letter

C2 - 32780924

AN - SCOPUS:85090227330

SN - 0926-9959

VL - 35

SP - e135-e138

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 2

ER -

MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this